Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Stock Rated “Equal Weight” in New Coverage at Barclays

Barclays began coverage on shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) in a research note released on Wednesday, Marketbeat.com reports. The firm issued an equal weight rating and a $10.00 price objective on the stock.

Other analysts also recently issued reports about the stock. Mizuho reduced their target price on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Weiss Ratings upgraded Senseonics Holdings, Inc. Common Stock from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Finally, Wall Street Zen raised Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $13.00.

Senseonics Holdings, Inc. Common Stock Stock Down 0.4%

Shares of SENS opened at $8.98 on Wednesday. The stock has a market capitalization of $375.36 million, a price-to-earnings ratio of -4.03 and a beta of 1.02. Senseonics Holdings, Inc. Common Stock has a 1 year low of $4.79 and a 1 year high of $10.64. The business’s 50 day simple moving average is $8.89 and its 200-day simple moving average is $7.11. The company has a debt-to-equity ratio of 0.62, a current ratio of 6.74 and a quick ratio of 6.40.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.08). The business had revenue of $14.48 million during the quarter. Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%. As a group, equities analysts expect that Senseonics Holdings, Inc. Common Stock will post -2.31 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Douglas Roeder purchased 13,953 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average cost of $8.98 per share, with a total value of $125,297.94. Following the purchase, the director owned 171,191 shares in the company, valued at approximately $1,537,295.18. This trade represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SENS. Integrated Wealth Concepts LLC purchased a new position in Senseonics Holdings, Inc. Common Stock during the 2nd quarter valued at $36,000. Readystate Asset Management LP bought a new stake in shares of Senseonics Holdings, Inc. Common Stock during the second quarter worth $574,000. Penn Capital Management Company LLC bought a new stake in shares of Senseonics Holdings, Inc. Common Stock during the second quarter worth $535,000. Stonepine Capital Management LLC purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock during the second quarter valued at $276,502. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock during the second quarter valued at $102,000. Hedge funds and other institutional investors own 12.36% of the company’s stock.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc is a medical technology company focused on developing and commercializing continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to measure glucose levels continuously and provide data through a wearable transmitter and mobile application, supporting diabetes management and treatment decisions.

The company’s primary product is the Eversense CGM system, which uses a small sensor implanted under the skin and a removable, rechargeable transmitter worn over the sensor.